I have recently been attending a Leukemia & Lymphoma Society (LLS) support group meeting in Spring Hill, Florida, near Tampa. I don’t know as much about leukemia, lymphoma and other blood cancers as I would like, but I’m learning fast. Covering events like the American Society of Hematology (ASH) meetings last week also helps.
I was excited to hear the LLS was targeting four specific areas for new research funding–including one for high risk multiple myeloma patients. Here is the official LLS press release:
The Leukemia & Lymphoma Society Targets Research in Four Critical Areas of Unmet Medical Need
WHITE PLAINS, N.Y., Dec. 14, 2010 /PRNewswire — The Leukemia & Lymphoma Society (LLS) is taking an aggressive approach to tackling the challenge of improving outcomes for patients with cancers that remain stubbornly resistant to treatment. As it has for more than 62 years, LLS will continue to accept applications from the world’s best and brightest scientists to advance progress in all areas of blood cancer, and award grants based on merit. In addition LLS has identified four specific areas of need, and is soliciting applications from scientists and physicians who are working on these difficult problems.
“We are charting the course by identifying and prioritizing the areas of need and directing funding to research that shows the most promise for improving survival and quality of life for patients with these particular diseases,” said Louis DeGennaro, Ph.D., LLS chief mission officer. “LLS wants to deliver better treatments, faster, to patients, and we have developed an innovative, strategic approach to achieve this goal.”
LLS is issuing requests for proposals (RFP) from researchers working in the following areas:
•Identification and characterization of the leukemic stem cell in acute myeloid leukemia and myelodysplastic syndrome and the identification of potential targeted therapies
•Novel therapeutic strategies for non-cutaneous T-cell lymphoproliferative disorders
•Development of therapeutic strategies for the high risk myeloma patient
•Mechanisms underlying long term and late effects resulting from cancer treatment and the development measures to significantly reduce or prevent these toxicities
Applications responsive to these RFPs should be submitted under LLS’s Translational Research Program, a program designed to help accelerate the movement of promising discoveries from the lab to the clinic. A detailed description of the LLS Translational Research Program and application instructions are available here.
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society® (LLS) is the world’s largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.
Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. http://www.lls.org/.
The LLS does so much for blood cancer patients. They certainly help me!
Feel good and keep smiling! Pat